NASDAQ:MBOT - Nasdaq - US59503A2042 - Common Stock - Currency: USD
MICROBOT MEDICAL INC
NASDAQ:MBOT (2/10/2025, 8:11:33 PM)
Premarket: 2.24 -0.07 (-3.03%)2.31
-0.24 (-9.41%)
The current stock price of MBOT is 2.31 USD. In the past month the price increased by 19.69%. In the past year, price increased by 79.07%.
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements...
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.12 | 227.75B | ||
ISRG | INTUITIVE SURGICAL INC | 81.27 | 212.18B | ||
BSX | BOSTON SCIENTIFIC CORP | 42.3 | 156.49B | ||
SYK | STRYKER CORP | 32.21 | 149.67B | ||
MDT | MEDTRONIC PLC | 17.3 | 116.48B | ||
BDX | BECTON DICKINSON AND CO | 17.44 | 66.57B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.63 | 41.93B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.73 | 39.98B | ||
IDXX | IDEXX LABORATORIES INC | 41.33 | 38.07B | ||
RMD | RESMED INC | 26.99 | 35.02B | ||
DXCM | DEXCOM INC | 51.92 | 34.48B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.74 | 25.93B |
Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The company is headquartered in Hingham, Massachusetts and currently employs 22 full-time employees. The firm is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. The company eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.
MICROBOT MEDICAL INC
25 Recreation Park Dr Suite 108
Hingham MASSACHUSETTS 02043 US
CEO: Harel Gadot
Employees: 22
Company Website: http://www.microbotmedical.com/
Investor Relations: http://www.microbotmedical.com/investors/
Phone: 19089385561
The current stock price of MBOT is 2.31 USD.
The exchange symbol of MICROBOT MEDICAL INC is MBOT and it is listed on the Nasdaq exchange.
MBOT stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MBOT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MBOT.
MBOT does not pay a dividend.
MBOT does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.71).
The outstanding short interest for MBOT is 10.8% of its float.
ChartMill assigns a technical rating of 9 / 10 to MBOT. When comparing the yearly performance of all stocks, MBOT is one of the better performing stocks in the market, outperforming 97.38% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MBOT. The financial health of MBOT is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months MBOT reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS increased by 42.28% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -215.15% | ||
ROE | -294.25% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to MBOT. The Buy consensus is the average rating of analysts ratings from 7 analysts.